Updated NETs Clinical Trials

• Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT Carcinoma

  Conditions: Metastatic Differentiated Thyroid Gland Carcinoma; Metastatic NUT Carcinoma; Metastatic Thyroid Gland Anaplastic Carcinoma; Metastatic Thyroid Gland Medullary Carcinoma; Refractory Differentiated Thyroid Gland Carcinoma; Stage III Differentiated Thyroid Gland Carcinoma AJCC v8; Stage III Thyroid Gland Medullary Carcinoma AJCC v8; Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8; Stage IV Thyroid Gland Medullary Carcinoma AJCC v8; Unresectable Differentiated Thyroid Gland Carcinoma; Unresectable NUT Carcinoma; Unresectable Thyroid Gland Anaplastic Carcinoma; Unresectable Thyroid Gland Medullary Carcinoma Interventions: Procedure: Biopsy Procedure; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Enfortumab Vedotin; Procedure: Magnetic Resonance Imaging; Other: Survey Administration; Procedure: X-Ray Imaging Sponsors: Northwestern University; National Cancer Institute (NCI) Not yet recruiting

• The Impact of Long-term Isolation in Antarctica on Social Touch and Its Underlying Biological Mechanisms in Winter-over Crew Members, Assessed During Their Stay Using Standardized Touch Stimulation, Computer-based Touch Sensitivity Tests, Questionnaires and Biological Markers.

  Conditions: Social Isolation; Isolated Confined and Extreme Conditions Interventions: Other: No Intervention: Observational Cohort Sponsors: Vrije Universiteit Brussel; Belgium: Belgian Federal Science Policy Office (BELSPO); European Space Agency; Institut Polaire Français Paul-Emile Victor (IPEV) Not yet recruiting

• Stromal Desmoplastic Reaction as a Predictive Factor for Lymph Node Metastasis in Medullary Thyroid Cancer

  Conditions: Medullary Thyroid Carcinoma Interventions: Procedure: lobectomy with lymph node dissection Sponsors: Aristotle University Of Thessaloniki; University of Cagliari; University of Pisa; Universita di Verona; Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not yet recruiting

• Traction-Assisted Versus Conventional Endoscopic Submucosal Dissection for Rectal Neuroendocrine Tumors

  Conditions: Rectal Neuroendocrine Tumor Interventions: Procedure: Traction-Assisted Endoscopic Submucosal Dissection; Procedure: Conventional Endoscopic Submucosal Dissection Sponsors: Pusan National University Hospital Not yet recruiting

• 3D MRE-Based Evaluation of Vestibular Schwannoma Mechanical Properties and Histological Features

  Conditions: Vestibular Schwannoma Sponsors: Shengjing Hospital Enrolling by invitation

• Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine Neoplasms

  Conditions: Neuroendocrine Neoplasm; Gastroenteropancreatic Neuroendocrine Neoplasm Interventions: Drug: Somatostatin Analogue(s) Sponsors: Washington University School of Medicine; Curium US LLC Not yet recruiting

• 68Ga-NYM215 in NENs

  Conditions: Neuroendocrine Neoplasms Interventions: Diagnostic Test: 68Ga-NYM215 PET/CT; Diagnostic Test: 68Ga-DOTATATE PET/CT Sponsors: Peking Union Medical College Hospital Not yet recruiting

• Lenvatinib Plus Chemotherapy for pNET Liver Metastases

  Conditions: Pancreatic Neuroendocrine Tumor With Liver Metastases Interventions: Drug: Lenvatinib; Drug: Chemotherapy Sponsors: Peking Union Medical College Hospital Recruiting

• A Comparative Study of Patients Undergoing Surgery for Pituitary Neuroendocrine Tumors Detected by Different Ways

  Conditions: Pituitary Neuroendocrine Tumors Sponsors: Beijing Tiantan Hospital Recruiting

• ZG005 Plus Etoposide and Cisplatin vs. Etoposide and Cisplatin as First-Line Treatment for Advanced Neuroendocrine Carcinoma

  Conditions: Neuroendocrine Carcinomas (NEC) Interventions: Drug: ZG005 for Injection; Drug: Etoposide Injection; Drug: Cisplatin Injection; Drug: ZG005 placebo for injection Sponsors: Suzhou Zelgen Biopharmaceuticals Co.,Ltd Not yet recruiting

• Beyond Psychological Distress: Implementation of a Dyadic Behavioral Intervention Targeting Neuroendocrine and mRNA Translational Pathways in Late-Stage Breast Cancer

  Conditions: CASA Intervention; Usual Care Interventions: Behavioral: The Caregivers-Patients Support to Cope with Advanced Cancer (CASA) is a five-session, manualized, meaning-centered psychotherapy developed for Puerto Rican patients and caregivers coping with advance; Behavioral: Control Condition. Includes CBT as the primary treatment approach for cancer patients and it is considered the usual care approach in these clinics, as well as one of the primar Sponsors: Ponce Medical School Foundation, Inc. Not yet recruiting

• Acute Effects of HIIT and MICT on Catestatin Dynamics in Young Males

  Conditions: Healthy Volunteers; Exercise Physiology; Autonomic Nervous System Regulation Interventions: Other: High-Intensity Interval Exercise; Other: Moderate-Intensity Continuous Exercise Sponsors: Firat University; The Scientific and Technological Research Council of Turkey Completed

• Optimizing Risk Assessment Through cfDNA in Pancreatic Neuroendocrine Tumors for Clinical Evaluation

  Conditions: Pancreatic Neuroendocrine Tumor Interventions: Other: cfDNA molecular profiling Sponsors: Massimo Falconi Active, not recruiting

• Thyroid Health Outcomes Registry for Surgery

  Conditions: Thyroid Diseases; Thyroid Neoplasms; Thyroid Cancer; Thyroid Nodules; Goiter; Medullary Thyroid Carcinoma; Thyroid Surgery for Benign Disease; Real-World Data; Adrenal Gland Neoplasms; Adrenal Cancer; Endocrine Surgery; Neck Dissection Sponsors: Pirogov Russian National Research Medical University Not yet recruiting

• China Treatment Trial for Tumor in Sellar Region With Unruptured Intracranial Aneurysm

  Conditions: Unruptured Intracranial Aneurysms; Pituitary Neuroendocrine Tumor; Craniopharyngioma; Meningioma; Germinoma; Rathke Cleft Cysts; Chordoma; Optic Pathway Glioma; Hypothalamic Neoplasms Interventions: Procedure: Tumor resection followed by aneurysm treatment; Procedure: Aneurysm treatment followed by tumor resection; Other: Observation Sponsors: Cheng sen; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; West China Hospital; Xijing Hospital; Shandong Provincial Hospital; The First Affiliated Hospital of Anhui Medical University; First Affiliated Hospital of Chongqing Medical University; Shengjing Hospital; Lanzhou University Second Hospital; The First Hospital of Jilin University; People's Hospital of Xinjiang Uygur Autonomous Region; Guangdong Provincial Hospital of Traditional Chinese Medicine; Huashan Hospital; Jinling Hospital, China Not yet recruiting

• CyberKnife Radiotherapy for the Treatment of Schwannomas

  Conditions: Schwannoma, Vestibular Sponsors: Hartmann Oncology Radiotherapy Group, France; Institut Rafael Completed

• STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)

  Conditions: Adrenocortical Carcinoma; Pheochromocytoma; Paraganglioma Interventions: Drug: Ivonescimab Sponsors: M.D. Anderson Cancer Center; Summit Therapeutics Not yet recruiting

• Comparing DLL3 PET/CT to Standard Scans in Neuroendocrine Cancer

  Conditions: Neuroendocrine Tumors Interventions: Drug: 68Ga-PFD3 Sponsors: Tingting Yuan Recruiting

• TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors

  Conditions: Small Cell Lung Cancer ( SCLC ); Neuroendocrine Cancer; Malignant Pleural Mesotheliomas (Mpm); Synovial Sarcomas Interventions: Drug: TLN-499; Drug: Venetoclax Sponsors: Treeline Biosciences, Inc. Recruiting

• Temporal Interference Transcranial Alternating Current Stimulation for Major Depressive Disorder

  Conditions: Major Depressive Disorder (MDD) Interventions: Device: Temporal Interference transcranial Alternating Current Stimulation (TI-tACS); Device: Sham Temporal Interference transcranial Alternating Current Stimulation (TI-tACS); Device: Temporal Interference transcranial Alternating Current Stimulation (TI-tACS) Sponsors: Central South University; Second Xiangya Hospital of Central South University; Neuropsychiatric Institute of Fuzhou Second General Hospital; Affiliated Wuhan Mental Health Center of Huazhong University of Science and Technology; Affiliated WuTaiShan Hospital of Medical College of Yangzhou University; Xianyue Psychiatric Hospital, Xiamen Not yet recruiting

• DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

  Conditions: Small Cell Lung Cancer; Large Cell Neuroendocrine Lung Carcinoma; Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology; Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology Interventions: Drug: Obrixtamig; Drug: ZL-1310; Drug: Atezolizumab Sponsors: Boehringer Ingelheim; Zai Lab Not yet recruiting

• Autonomic and Peripheral Neurochemical Responses to Maximal Rowing Exercise

  Conditions: Healhty Interventions: Other: Maximal 6,000-m rowing ergometer test Sponsors: Poznan University of Physical Education; Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz Completed

• 211At-MABG in Adults With Advanced Neuroendocrine Cancers

  Conditions: Pheochromocytoma; Paraganglioma; Neuroendocrine Tumors; Medullary Thyroid Cancer; Bronchial Carcinoid; Gastroenteropancreatic Neuroendocrine Neoplasm Interventions: Drug: 1 MBq/k of 211At-MABG Fractionated; Drug: 2 MBq/k1 of 211At-MABG Fractionated; Drug: 4 MBq/k of 211At-MABG Fractionated Sponsors: University of Pennsylvania; National Institutes of Health (NIH); National Cancer Institute (NCI) Not yet recruiting

• A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies

  Conditions: Neuroendocrine Tumors, NET; Pheochromocytoma/Paraganglioma; SSTR-expressing Tumors; Medullary Thyroid Carcinoma Interventions: Diagnostic Test: 68Ga-DOTATATE PET/CT; Diagnostic Test: 18F-AmBF3-TATE PET/CT Sponsors: British Columbia Cancer Agency Not yet recruiting

• DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  Conditions: Extrapulmonary Neuroendocrine Cancer (epNEC) Interventions: Drug: Obrixtamig; Drug: Carboplatin; Drug: Etoposide; Device: Ventana DLL3 RxDx assay Sponsors: Boehringer Ingelheim Recruiting

• Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease

  Conditions: Recurrent Small Cell Lung Cancer; Extensive-Stage Small Cell Lung Cancer; Small Cell Lung Cancer; Small Cell Lung Carcinoma; Refractory Small Cell Lung Cancer; Extrapulmonary Small Cell Carcinoma; Neuroendocrine Carcinoma; Poorly Differentiated Neuroendocrine Carcinoma; High-Grade Neuroendocrine Carcinoma Interventions: Drug: Autologous B7-H3 CAR T; Drug: Cyclophosphamide; Drug: Fludarabine Sponsors: National Cancer Institute (NCI) Recruiting

• Remotely-Delivered Cognitive Behavioral Stress Management for Breast Cancer (R-CBSM)

  Conditions: Breast Cancer Interventions: Behavioral: Remotely Delivered Cognitive Behavioral Stress Management Intervention (R-CBSM); Behavioral: Standard of Care Survivorship Care Planning Sponsors: University of Miami; National Cancer Institute (NCI) Recruiting

• Mind-Body Group Interventions for Psychological Distress in Young Breast Cancer Survivors

  Conditions: Breast Cancer Interventions: Behavioral: Breath-Body-Mind (BBM); Behavioral: Survivorship education program (SEP) Sponsors: University of Alabama at Birmingham Not yet recruiting

• A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)

  Conditions: Small Cell Lung Cancer (SCLC ); Extrapulmonary Neuroendocrine Carcinoma (EP-NEC); Gastroenteropancreatic NEC (GEP NEC); Neuroendocrine Prostate Cancer (NEPC) Interventions: Biological: ML261 Sponsors: Moonlight Bio, Inc Recruiting

• ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1

  Conditions: Merkel Cell Carcinoma; Merkel Cell Carcinoma, Stage III; Merkel Cell Carcinoma, Stage IV Interventions: Drug: ASTX727 + retifanlimab Sponsors: University of Wisconsin, Madison Not yet recruiting

• DLL3-Targeted PET/CT in Neuroendocrine Carcinoma

  Conditions: DLL3-expressing Tumors; PET / CT; Neuroendocrine Cancer Interventions: Diagnostic Test: Diagnostic Test: conventional imaging (CT, MRI or 18F-FDG PET/CT), DLL3-targeted PET/CT Sponsors: The First Affiliated Hospital of Xiamen University Recruiting

• The IUPU-PPGL Score: A Imaging-Based Tool for Stratifying Surgical Complexity in Patients With Pheochromocytoma and Paragangliom（PPGL）

  Conditions: Risk Grading System; Pheochromocytoma and Paraganglioma (PPGL); Quantitative Assessment Interventions: Other: observational diagnostic model development Sponsors: Peking University First Hospital Completed

• TheraSphere Japan Pre-Market Study

  Conditions: Liver Neoplasms Interventions: Device: TheraSphere Y-90 glass microsphere Sponsors: Boston Scientific Corporation Recruiting

• Oral and Salivary Biomarkers Associated With Stroke

  Conditions: Stroke Sponsors: University Hospital Center (CHU) of Constantine, Algeria Not yet recruiting

• Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment

  Conditions: Neuroendocrine Tumors Sponsors: Ipsen Recruiting

• Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma

  Conditions: Advanced Pheochromocytoma and Paraganglioma; PCPG Interventions: Drug: ONC206; Drug: ONC206: Dose 1; Drug: ONC206: Dose 2 Sponsors: Jazz Pharmaceuticals Recruiting

• Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

  Conditions: Large Cell Neuroendocrine Carcinoma; Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC); Extrapulmonary Neuroendocrine Carcinoma (EP-NEC); Small Cell Lung Cancer (SCLC); Gastroenteropancreatic NEC (GEP NEC); NEC of the Bladder; Other DLL3 Expressing epNEC Interventions: Drug: [212Pb]Pb-MP0712; Other: [203Pb]Pb-MP0712 Sponsors: Molecular Partners AG; Orano Med LLC Recruiting

• Intermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a Tumor

  Conditions: Tumor-associated Hyperinsulinism (Tumor HI) Interventions: Drug: Ersodetug (9 mg/kg) + SOC Sponsors: Rezolute Available

• Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS)

  Conditions: Polycystic Ovarian Syndrome in Adolescent Females; Obesity (Disorder) Interventions: Drug: GLP-1 Receptor Agonists Sponsors: Nemours Children's Clinic Recruiting

• Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

  Conditions: GEP-NET; Gastroenteropancreatic Neuroendocrine Tumor; Gastroenteropancreatic Neuroendocrine Tumor Disease; Neuroendocrine Tumors; Carcinoid; Carcinoid Tumor; Pancreatic NET; Solid Tumor; Somatostatin Receptor Interventions: Drug: RYZ401 Sponsors: RayzeBio, Inc. Recruiting

• Cultural Adaptation of an Educational Tool in Medullary Thyroid Cancer

  Conditions: Medullary Thyroid Cancer (MTC); Cultural Adaptation Interventions: Other: Interviews Sponsors: M.D. Anderson Cancer Center Recruiting

• Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

  Conditions: Carcinoid Syndrome; Carcinoid; Carcinoid Tumor; Carcinoid Tumor of Ileum; Carcinoid Tumor of Cecum; Carcinoid Tumor of Liver; Carcinoid Tumor of Pancreas; Carcinoid Syndrome Diarrhea; Carcinoid Intestine Tumor Interventions: Drug: Paltusotine; Drug: Placebo Sponsors: Crinetics Pharmaceuticals Inc. Recruiting

• Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

  Conditions: Small Cell Lung Cancer Metastatic or Locally Advanced; Neuroendocrine Cancer; Metastatic Neuroendocrine Prostate Cancer; Metastatic Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma; Metastatic Advanced Merkel Cell Carcinoma; Locally Advanced Large Cell Neuroendocrine Carcinoma of the Lung; Locally Advanced Extrapulmonary Neuroendocrine Carcinoma; Locally Advanced Neuroendocrine Prostate Cancer; Locally Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine; Locally Advanced Merkel Cell Carcinoma; Metastatic Large Cell Neuroendocrine Carcinoma of the Lung Interventions: Drug: BL-M14D1 Sponsors: SystImmune Inc. Recruiting

• Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab

  Conditions: Advanced Neuroendocrine Carcinomas of The Digestive System; Advanced Neuroendocrine Carcinomas Unknown Primary Origin Interventions: Drug: Tarlatamab; Drug: standard of care second-line chemotherapy (FOLFIRI) Sponsors: Grupo Espanol de Tumores Neuroendocrinos; Amgen Terminated

• Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)

  Conditions: Metastatic/Locally Advanced Small-Cell Lung Cancer; Metastatic/Locally Advanced Poorly Differentiated NEC Interventions: Drug: Tarlatamab Sponsors: Gustave Roussy, Cancer Campus, Grand Paris; Amgen Recruiting

• Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

  Conditions: Small Cell Lung Carcinoma; Large Cell Neuroendocrine Carcinoma of the Lung; Neuroendocrine Prostate Cancer; Gastroenteropancreatic Neuroendocrine Carcinoma; Non-prostate Extrapulmonary Neuroendocrine Carcinoma; Cervical Neuroendocrine Carcinoma; Thymic Neuroendocrine Carcinoma; Genitourinary Neuroendocrine Carcinoma; Unknown Primary Neuroendocrine Carcinomas; Merkel Cell Carcinoma; Medullary Thyroid Carcinoma Interventions: Drug: 225Ac-ETN029; Drug: 111In-ETN029 Sponsors: Novartis Pharmaceuticals Recruiting

• Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

  Conditions: Pancreatic Neuroendocrine Tumor (pNET); Extra-Pancreatic Neuroendocrine Tumor (epNET) Interventions: Drug: Zanzalintinib; Drug: Everolimus Sponsors: Exelixis Recruiting

• Affect-based Impulsivity in Borderline Personality Disorder

  Conditions: Borderline Personality Disorder (BPD); Healthy Controls Group - Age and Sex-matched Interventions: Behavioral: Stress Induction Sponsors: University of North Carolina, Chapel Hill; North Carolina Translational and Clinical Sciences Institute Completed

• A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism

  Conditions: Tumor Hyperinsulinism (Tumor HI) Interventions: Drug: Ersodetug Sponsors: Rezolute Recruiting

• Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors

  Conditions: Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs) Interventions: Drug: 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 16 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm.; Drug: 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 8 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm.; Drug: Amino acid solution; Drug: Lanreotide (Autogel formulation) or Octreotide LAR Sponsors: Grupo Espanol de Tumores Neuroendocrinos; Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE) Recruiting